News
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...
The Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC) was terminated in April. After sweeping cuts ...
The deal gives Lilly access to the company’s RNA-editing platform to develop therapies for sensorineural hearing loss.
US President Donald Trump has resurrected a drug pricing plan that equates to International Reference Pricing.
AGC Biologics has collaborated with Quell Therapeutics to advance the development of several T-regulatory (Treg) cell therapy ...
The FDA approved 19 biosimilars in 2024, a sharp jump from the five greenlit by the agency in 2023. 2024 saw the highest ...
The executive order instructs the FDA to expedite the approval process for domestic pharmaceutical manufacturing facilities.
Pathos AI has raised $365m in a Series D funding round to widen its AI-enabled platform to advance the development of ...
The US Food and Drug Administration has granted approval to Amneal Pharmaceuticals’ Brekiya (dihydroergotamine (DHE) mesylate ...
Artificial Intelligence (AI) is now used throughout clinical trials, from recruitment to analysis – but are regulators ...
AbbVie has signed a collaboration and licensing agreement with US-based ADARx Pharmaceuticals, committing $335m upfront to ...
The FDA has approved MSD’s Welireg for rare adrenal tumours, and AbbVie’s Emrelis for treating c-Met+ lung cancer patients.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results